Antibody-Drug Conjugate Targeting Tumor Scaffolding Shows Promise in Trial

European Organisation for Research and Treatment of Cancer

Barcelona, Spain: An antibody-drug conjugate (ADC), called micvotabart pelidotin, or MICVO, has produced positive results in an early trial with head and neck cancer patients.

The results, to be presented on Thursday at the 38th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, are from a phase I trial in patients with recurrent or metastatic head and neck squamous cell carcinoma, whose tumours had continued to grow despite treatment with existing cancer drugs.

MICVO has been designed to target the extracellular matrix, the supportive scaffolding present throughout a tumour, and then to release a powerful drug to kill nearby cancer cells and stimulate an immune response against the tumour.

The results will be presented by Faye Johnson, professor of Thoracic/ Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, USA. She said: "Patients with recurrent or metastatic head and neck squamous cell carcinoma do not have effective treatment options once their cancers stop responding to standard therapies, such as chemotherapy and immunotherapy. Currently available treatments produce tumour responses in fewer than 15% of cases. Even when responses occur, they are often short-lived, with disease progression typically occurring in less than two months and overall survival averaging less than six months.

"The need for new treatments is substantial and continues to grow. In the United States, more than 30,000 patients begin first-line treatment for this type of cancer each year. Approximately 70% will see their disease progress and require second-line treatment, creating a population of roughly 21,000 patients annually who have very limited therapeutic options."

The research included 36 patients with recurrent or metastatic head and neck squamous cell carcinoma treated at one of 29 cancer centres enrolling patients across the USA and Europe. The majority of patients had already had two or more cancer treatments.

All the patients were treated with MICVO at 5.4 milligrams per kilogram of total body weight, every three weeks, up to a dose cap of 80 kilograms for males and 70 kilograms for females. Researchers were able to assess the antitumour effects of the drug in 33 of these patients.

Researchers found that MICVO had a confirmed overall response rate (where the cancer shrinks by at least 30%) of 39%, including one patient with a complete response, and an average (median) progression-free survival (meaning the cancer does not grow or spread) of 6.7 months. The overall survival probability at one year was 81%. Researchers found similar responses in patients with different cancer subtypes including HPV-positive and HPV-unrelated cancers and in those previously treated with taxanes and/or EGFR inhibitors.

Professor Johnson said: "Most of the responses were rapid and deep, occurring by the first assessment scans and resulting in a greater than 50% reduction in tumour size.

"Safety of the drug was manageable and consistent with prolonged exposure to auristatin, MICVO's anti-cancer drug. In the context of the benefit observed for patients, the overall benefit to risk profile provides meaningful promise for patients that lack effective treatment options."

Serious (grade 3 or higher) treatment-related side effects experienced by two or more patients included neuropathy (nerve damage), raised liver enzymes, rash and low levels of white blood cells.

MICVO targets a protein called extradomain-B of fibronectin (EDB+FN), which is often found at high levels in the extracellular matrix of tumours, including head and neck cancer, but is largely absent from other parts of the body. After binding to EDB+FN, MICVO releases a potent chemotherapy drug called auristatin.

The makers of MICVO, Pyxis Oncology, plan to begin a global phase III trial in mid-2027 for patients with recurrent or metastatic head and neck squamous cell carcinoma who have already had at least one previous treatment. Researchers will continue to evaluate patients already treated with MICVO within clinical trials, both as a single treatment and in combination with other cancer drugs.

Professor Elena Garralda, chair of the EORTC-NCI-AACR Symposium (ENA) and co-director of the Vall d'Hebron Institute of Oncology's clinical research programme, was not involved with the study. She commented: "Head and neck squamous cell carcinoma is a type of cancer that begins in the cells lining the mouth, throat and larynx. It is a common form of cancer, and it has become more common over recent decades. Although we have treatments for this type of cancer, we need more options for patients when our existing treatments fail. These early results show positive signs of clinical efficacy for MICVO with manageable side effects for the patients taking part."

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.